Diagnostic Role and Prognostic Impact of PSAP Immunohistochemistry: A Tissue Microarray Study on 31,358 Cancer Tissues
-
Published:2023-10-18
Issue:20
Volume:13
Page:3242
-
ISSN:2075-4418
-
Container-title:Diagnostics
-
language:en
-
Short-container-title:Diagnostics
Author:
Tribian Laura Sophie1, Lennartz Maximilian1ORCID, Höflmayer Doris1, de Wispelaere Noémi2, Dwertmann Rico Sebastian1, von Bargen Clara1, Kind Simon1, Reiswich Viktor1, Viehweger Florian1, Lutz Florian1, Bertram Veit1, Fraune Christoph1, Gorbokon Natalia1, Weidemann Sören1, Hube-Magg Claudia1ORCID, Menz Anne1, Uhlig Ria1, Krech Till13, Hinsch Andrea1, Burandt Eike1, Sauter Guido1, Simon Ronald1ORCID, Kluth Martina1, Steurer Stefan1, Marx Andreas H.4, Lebok Patrick13, Dum David1, Minner Sarah1, Jacobsen Frank1, Clauditz Till S.1ORCID, Bernreuther Christian1
Affiliation:
1. Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany 2. Department of General, Visceral, and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany 3. Institute of Pathology, Clinical Center Osnabrueck, 49076 Osnabrueck, Germany 4. Department of Pathology, Academic Hospital Fuerth, 90766 Fuerth, Germany
Abstract
Prostate-specific acid phosphatase (PSAP) is a marker for prostate cancer. To assess the specificity and prognostic impact of PSAP, 14,137 samples from 127 different tumor (sub)types, 17,747 prostate cancers, and 76 different normal tissue types were analyzed via immunohistochemistry in a tissue microarray format. In normal tissues, PSAP staining was limited to the prostate epithelial cells. In prostate cancers, PSAP was seen in 100% of Gleason 3 + 3, 95.5% of Gleason 4 + 4, 93.8% of recurrent cancer under androgen deprivation therapy, 91.0% of Gleason 5 + 5, and 31.2% of small cell neuroendocrine cancer. In non-prostatic tumors, PSAP immunostaining was only found in 3.2% of pancreatic neuroendocrine tumors and in 0.8% of diffuse-type gastric adenocarcinomas. In prostate cancer, reduced PSAP staining was strongly linked to an advanced pT stage, a high classical and quantitative Gleason score, lymph node metastasis, high pre-operative PSA levels, early PSA recurrence (p < 0.0001 each), high androgen receptor expression, and TMPRSS2:ERG fusions. A low level of PSAP expression was linked to PSA recurrence independent of pre- and postoperative prognostic markers in ERG-negative cancers. Positive PSAP immunostaining is highly specific for prostate cancer. Reduced PSAP expression is associated with aggressive prostate cancers. These findings make PSAP a candidate marker for prognostic multiparameter panels in ERG-negative prostate cancers.
Subject
Clinical Biochemistry
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|